Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
6.74
-0.50 (-6.91%)
Mar 5, 2026, 12:52 PM EST - Market open
Lexeo Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Lexeo Therapeutics stock have an average target of 18.6, with a low estimate of 10 and a high estimate of 30. The average target predicts an increase of 175.96% from the current stock price of 6.74.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 13, 2026.
Analyst Ratings
The average analyst rating for Lexeo Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 5 | 5 | 5 |
| Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +152.23% | Jan 13, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $10 | Strong Buy | Maintains | $13 → $10 | +48.37% | Jan 13, 2026 |
| Raymond James | Raymond James | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +270.92% | Dec 18, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +152.23% | Dec 11, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $19 | Buy | Initiates | $19 | +181.90% | Dec 1, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.01
from -3.09
EPS Next Year
-1.55
from -2.01
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.90 | -1.08 | ||||
| Avg | -2.01 | -1.55 | ||||
| Low | -2.21 | -2.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.